ESA's Sophie Adenot Processes Blood Stem Cells in DNA Nano Therapeutics-3 on ISS
Updated
Updated · European Space Agency · May 28
ESA's Sophie Adenot Processes Blood Stem Cells in DNA Nano Therapeutics-3 on ISS
1 articles · Updated · European Space Agency · May 28
Summary
Sophie Adenot processed blood stem cell samples aboard the ISS for ESA's DNA Nano Therapeutics-3 experiment, a microgravity study aimed at scaling up clinical-grade stem cell production.
The work is designed to show whether microgravity can improve stem cell quality and yield, with potential applications in treating blood diseases and cancer.
The samples were handled inside the Life Science Glovebox in the Kibo module, a sealed workspace built to prevent contamination and protect both crew safety and research integrity.
ESA says the experiment could also broaden commercial biomedical research opportunities in orbit as space-based life science work expands.
Will life-saving medicines manufactured in space be affordable for patients on Earth?
Microgravity can both help and harm cells. How do we harness its benefits for medicine while avoiding the risks?
ISS Expedition 74 Biotechnology Research (2026): Microgravity-Driven Advances in Stem Cells, Nanomaterials, and Medical Innovation
Overview
As of late May 2026, Expedition 74 on the International Space Station is carrying out a comprehensive biotechnology research program focused on improving human health in space and on Earth. By using the unique microgravity environment, the crew—led by NASA flight engineer Jessica Meir—investigates how biological processes like cartilage repair work without gravity. These experiments are providing new insights into complex biology, but the results are still being analyzed and have not yet been published. The ongoing research aims to unlock medical advances that could benefit both astronauts and people on Earth.